![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, August 19, 2010 9:08:15 AM
INDIANAPOLIS, Aug 19, 2010 (BUSINESS WIRE) -- Positron Corporation
(OTCBB:POSC), announced it has signed an agreement with Covidien (NYSE:COV), a
leading global provider of healthcare products, under which Covidien will
provide technical assistance to Positron in connection with Positron's
development of technology to automate the compounding of radiopharmaceuticals.
The agreement combines Covidien's expertise in radiopharmaceuticals and
regulatory issues with Positron's expertise in automation and
radiopharmaceuticals. Automating the distribution of radiopharmaceuticals has
many benefits, ranging from worker safety to cost savings to enhanced customer
service.
"Positron continues to provide unique solutions to the molecular imaging
community," said John Zehner, COO of Positron. "This agreement provides Positron
with various advantages and additional resources. We are very excited to
collaborate with Covidien on this project."
About Positron: Positron is a molecular imaging company focused on Nuclear
Cardiology. Positron utilizes its proprietary product line to provide unique
solutions to the Nuclear Medicine community ranging from imaging to
radiopharmaceutical distribution. Positron products include: the Attrius(TM), a
PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear
Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the
Tech-Assist(TM), a radiopharmaceutical injection shield. More information about
Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended.
These statements are based on many assumptions and estimates and are not
guarantees of future performance and may involve known and unknown risks,
uncertainties and other factors which may cause the actual results, performance
or achievements of Positron Corporation to be materially different from future
results, performance or achievements expressed or implied by such
forward-looking statements. Positron assumes no obligation to publicly update or
revise these forward-looking statements for any reason, or to update the reasons
actual results could differ materially from those anticipated in these
forward-looking statements, even if new information becomes available in the
future. Our actual results may differ materially from the results anticipated in
these forward-looking statements due to a variety of factors, including, without
limitation those set forth as "Risk Factors" in our filings with the Securities
and Exchange Commission.
SOURCE: Positron Corporation
CONTACT:
Positron Corporation
John Zehner, 317-576-0183
Copyright Business Wire 2010
-0-
KEYWORD: United States
North America
Indiana
INDUSTRY KEYWORD: Health
Biotechnology
Cardiology
Medical Devices
Pharmaceutical
Radiology
Medical Supplies
General Health
SUBJECT CODE: Contract/Agreement
Source: Comtext Market News
Maybacks Global and Inventel Products To Launch Global 24 Hour Shopping Channel • AHRO • Sep 3, 2024 9:15 AM
UC Asset announces plan of management stock buyback • UCASU • Sep 3, 2024 9:00 AM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM